Compare APA & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APA | GKOS |
|---|---|---|
| Founded | 1954 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 10.9B |
| IPO Year | 2021 | 2015 |
| Metric | APA | GKOS |
|---|---|---|
| Price | $42.38 | $181.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 23 | 12 |
| Target Price | $31.96 | ★ $126.92 |
| AVG Volume (30 Days) | ★ 5.8M | 876.4K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | ★ 75.77 | N/A |
| EPS | ★ 3.37 | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | $3.86 | $23.32 |
| Revenue Next Year | N/A | $27.43 |
| P/E Ratio | $12.22 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $21.64 | $73.16 |
| 52 Week High | $45.66 | $191.62 |
| Indicator | APA | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 61.50 | 60.38 |
| Support Level | $35.11 | $175.04 |
| Resistance Level | $45.36 | $184.00 |
| Average True Range (ATR) | 1.40 | 6.01 |
| MACD | -0.02 | -1.59 |
| Stochastic Oscillator | 60.96 | 39.63 |
APA Corp is an independent exploration and production company. It develops and produces crude oil, natural gas, and natural gas liquids. The company's business has oil and gas operations in four segments: Egypt, the North Sea, Suriname, and the U.S. The company generates the majority of its revenue from the U.S. reporting segment. The company also has exploration interests in Uruguay, Alaska, and other international locations.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.